ArticleACS sensors2025
Single-Molecule Array (Simoa) Technology as a Highly Sensitive Screening Tool for Protein-Protein Interactions.
Article in ACS sensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ARX mutation-associated interneuron defects provide insights into mechanisms underlying developmental epilepsies.Brain : a journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Transcription factor (TF) interactions are generally considered to be weak and transient, which enables the dynamic assembly and disassembly of transcription complexes. While advantageous for modulating cellular physiology, requiring rapid adaptation, these characteristics make it challenging to identify and study TF interactions using conventional methodologies. To overcome this issue, we have adapted an ultrasensitive single-molecule array (Simoa) assay, typically used for biomarker detection, to screen for and identify TF-TF interactions. Leveraging Simoa-based digital ELISA, we have screened the human transcription factor library for interaction partners of ARX (aristaless-related homeobox), a transcription factor associated with a wide spectrum of neurodevelopmental disorders. Our successful application of Simoa technology to a high-throughput screening for protein interaction partners opens up new opportunities to study transcription factor-transcription factor interactions, especially those that have been elusive to detect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.